|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reck M, Heigener DF, Mok T, Soria JC and
Rabe KF: Management of non-small-cell lung cancer: Recent
developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oxnard GR, Binder A and Janne PA: New
targetable oncogenes in non-small-cell lung cancer. J Clin Oncol.
31:1097–1104. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: Geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moasser MM: The oncogene HER2: Its
signaling and transforming functions and its role in human cancer
pathogenesis. Oncogene. 26:6469–6487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu D and Hung MC: Overexpression of ErbB2
in cancer and ErbB2-targeting strategies. Oncogene. 19:6115–6121.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tan D, Deeb G, Wang J, Slocum HK, Winston
J, Wiseman S, Beck A, Sait S, Anderson T and Nwogu C: HER-2/neu
protein expression and gene alteration in stage I–IIIA
non-small-cell lung cancer: A study of 140 cases using a
combination of high throughput tissue microarray,
immunohistochemistry, and fluorescent in situ hybridization. Diagn
Mol Pathol. 12:201–211. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pellegrini C, Falleni M, Marchetti A,
Cassani B, Miozzo M, Buttitta F, Roncalli M, Coggi G and Bosari S:
HER-2/Neu alterations in non-small cell lung cancer: A
comprehensive evaluation by real time reverse transcription-PCR,
fluorescence in situ hybridization, and immunohistochemistry. Clin
Cancer Res. 9:3645–3652. 2003.PubMed/NCBI
|
|
9
|
Cappuzzo F, Varella-Garcia M, Shigematsu
H, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V,
Gregorc V, Toschi L, et al: Increased HER2 gene copy number is
associated with response to gefitinib therapy in epidermal growth
factor receptor-positive non-small-cell lung cancer patients. J
Clin Oncol. 23:5007–5018. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Swanton C, Futreal A and Eisen T:
Her2-targeted therapies in non-small cell lung cancer. Clin Cancer
Res. 12:4377s–4383s. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Stephens P, Hunter C, Bignell G, Edkins S,
Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, et al:
Lung cancer: Intragenic ERBB2 kinase mutations in tumours. Nature.
431:525–526. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shigematsu H, Takahashi T, Nomura M,
Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S,
Shimizu N, et al: Somatic mutations of the HER2 kinase domain in
lung adenocarcinomas. Cancer Res. 65:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamamoto H, Higasa K, Sakaguchi M, Shien
K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N,
et al: Novel germline mutation in the transmembrane domain of HER2
in familial lung adenocarcinomas. J Natl Cancer Inst.
106:djt3382014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Greulich H, Kaplan B, Mertins P, Chen TH,
Tanaka KE, Yun CH, Zhang X, Lee SH, Cho J, Ambrogio L, et al:
Functional analysis of receptor tyrosine kinase mutations in lung
cancer identifies oncogenic extracellular domain mutations of
ERBB2. Proc Natl Acad Sci USA. 109:14476–14481. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mar N, Vredenburgh JJ and Wasser JS:
Targeting HER2 in the treatment of non-small cell lung cancer. Lung
Cancer. 87:220–225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
De G, rève J, Teugels E, Geers C, Decoster
L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P and
Schallier D: Clinical activity of afatinib (BIBW 2992) in patients
with lung adenocarcinoma with mutations in the kinase domain of
HER2/neu. Lung Cancer. 76:123–127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mazieres J, Peters S, Lepage B, Cortot AB,
Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban
T, et al: Lung cancer that harbors an HER2 mutation: Epidemiologic
characteristics and therapeutic perspectives. J Clin Oncol.
31:1997–2003. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Suzawa K, Toyooka S, Sakaguchi M, Morita
M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y,
et al: Antitumor effect of afatinib, as a human epidermal growth
factor receptor 2-targeted therapy, in lung cancers harboring HER2
oncogene alterations. Cancer Sci. 107:45–52. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chan A, Delaloge S, Holmes FA, Moy B,
Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz
G, et al: Neratinib after trastuzumab-based adjuvant therapy in
patients with HER2-positive breast cancer (ExteNET): A multicentre,
randomised, double-blind, placebo-controlled, phase 3 trial. Lancet
Oncol. 17:367–377. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gandhi L, Besse B, Mazieres J, Waqar S,
Cortot A, Barlesi F, Quoix E, Otterson G, Ettinger D, Horn L, et
al: MA04.02 Neratinib ± temsirolimus in HER2-mutant lung cancers:
An international, randomized phase II study. J Thorac Oncol. 12
Suppl:S358–S359. 2017. View Article : Google Scholar
|
|
21
|
Mazieres J, Barlesi F, Filleron T, Besse
B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, et
al: Lung cancer patients with HER2 mutations treated with
chemotherapy and HER2-targeted drugs: results from the European
EUHER2 cohort. Ann Oncol. 27:281–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gandhi J, Zhang J, Xie Y, Soh J,
Shigematsu H, Zhang W, Yamamoto H, Peyton M, Girard L, Lockwood WW,
et al: Alterations in genes of the EGFR signaling pathway and their
relationship to EGFR tyrosine kinase inhibitor sensitivity in lung
cancer cell lines. PLoS One. 4:e45762009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Girard L, Zöchbauer-Müller S, Virmani AK,
Gazdar AF and Minna JD: Genome-wide allelotyping of lung cancer
identifies new regions of allelic loss, differences between small
cell lung cancer and non-small cell lung cancer, and loci
clustering. Cancer Res. 60:4894–4906. 2000.PubMed/NCBI
|
|
24
|
Sakaguchi M, Watanabe M, Kinoshita R, Kaku
H, Ueki H, Futami J, Murata H, Inoue Y, Li SA, Huang P, et al:
Dramatic increase in expression of a transgene by insertion of
promoters downstream of the cargo gene. Mol Biotechnol. 56:621–630.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shien K, Toyooka S, Ichimura K, Soh J,
Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, et al:
Prognostic impact of cancer stem cell-related markers in non-small
cell lung cancer patients treated with induction chemoradiotherapy.
Lung Cancer. 77:162–167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engelman JA, Janne PA, Mermel C, Pearlberg
J, Mukohara T, Fleet C, Cichowski K, Johnson BE and Cantley LC:
ErbB-3 mediates phosphoinositide 3-kinase activity in
gefitinib-sensitive non-small cell lung cancer cell lines. Proc
Natl Acad Sc USA. 102:3788–3793. 2005. View Article : Google Scholar
|
|
29
|
Schwab CL, English DP, Black J, Bellone S,
Lopez S, Cocco E, Bonazzoli E, Bussi B, Predolini F, Ferrari F, et
al: Neratinib shows efficacy in the treatment of HER2 amplified
carcinosarcoma in vitro and in vivo. Gynecol Oncol. 139:112–117.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Menderes G, Bonazzoli E, Bellone S, Black
JD, Lopez S, Pettinella F, Masserdotti A, Zammataro L, Litkouhi B,
Ratner E, et al: Efficacy of neratinib in the treatment of
HER2/neu-amplified epithelial ovarian carcinoma in vitro and in
vivo. Med Oncol. 34:912017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kohsaka S, Nagano M, Ueno T, Suehara Y,
Hayashi T, Shimada N, Takahashi K, Suzuki K, Takamochi K, Takahashi
F and Mano H: A method of high-throughput functional evaluation of
EGFR gene variants of unknown significance in cancer. Sci Transl
Med. 9(pii): eaan65662017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Minami Y, Shimamura T, Shah K, LaFramboise
T, Glatt KA, Liniker E, Borgman CL, Haringsma HJ, Feng W, Weir BA,
et al: The major lung cancer-derived mutants of ERBB2 are oncogenic
and are associated with sensitivity to the irreversible EGFR/ERBB2
inhibitor HKI-272. Oncogene. 26:5023–5027. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tai W, Mahato R and Cheng K: The role of
HER2 in cancer therapy and targeted drug delivery. J Control
Release. 146:264–275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang SE, Narasanna A, Perez-Torres M,
Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK and
Arteaga CL: HER2 kinase domain mutation results in constitutive
phosphorylation and activation of HER2 and EGFR and resistance to
EGFR tyrosine kinase inhibitors. Cancer Cell. 10:25–38. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ou SI, Schrock AB, Bocharov EV, Klempner
SJ, Haddad CK, Steinecker G, Johnson M, Gitlitz BJ, Chung J,
Campregher PV, et al: HER2 transmembrane domain (TMD) mutations
(V659/G660) that stabilize homo- and heterodimerization are rare
oncogenic drivers in lung adenocarcinoma that respond to Afatinib.
J Thorac Oncol. 12:446–457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Eng J, Hsu M, Chaft JE, Kris MG, Arcila ME
and Li BT: Outcomes of chemotherapies and HER2 directed therapies
in advanced HER2-mutant lung cancers. Lung Cancer. 99:53–56. 2016.
View Article : Google Scholar : PubMed/NCBI
|
